Folisanin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Folisanin

What is Folisanin and What Class of Medicine Does It Belong To?

Folisanin is a medicinal preparation whose active component is Folic Acid, also known as Vitamin B9 or Pteroylglutamic acid. It is classified pharmacologically as a water-soluble vitamin and a Hematopoietic Agent, a term used for agents that aid in the formation of blood components. The preparation is designed to supplement the body’s supply of this essential micronutrient, a requirement for various physiological processes.

The function of Folisanin is to act as an external source of this compound. As a Hematopoietic Agent, its role is to support the creation of healthy blood cells. Folic Acid is involved in the synthesis of DNA and other genetic material. While often available as an over-the-counter (OTC) supplement for general supplementation, higher therapeutic concentrations may require a prescription (Rx) status.


Is Folisanin a Natural Nutrient or a Synthetic Compound?

The active ingredient in Folisanin, Folic Acid (Pteroylglutamic acid), is a synthetic compound used as a stable metabolic precursor to the active folates found naturally in food sources. While Folic Acid is an essential micronutrient vital for health, the specific form used in this preparation is chemically synthesized. This synthesis ensures a consistent and stable pharmaceutical product.

The body cannot produce Vitamin B9 on its own, making dietary intake or supplementation necessary. Folic Acid requires specific metabolic conversion steps within the body to be transformed into its biologically active forms. This controlled, synthetic preparation provides a stable dose for targeted nutritional intervention, often utilized during periods of increased physiological demand for blood cell synthesis.


What Is the General Purpose of Taking Folisanin?

The general purpose of taking Folisanin is to prevent and correct states of Vitamin B9 deficiency (Hypovitaminosis). This deficiency can compromise fundamental systemic functions. Folic Acid acts as a coenzyme for the synthesis of DNA and the subsequent maturation of red blood cells (Erythropoiesis). By providing this precursor, Folisanin helps maintain the integrity of systems with high cellular turnover, supporting the body’s ability to create and utilize new cells.

What side effects are possible with Folisanin?

Possible side effects and safety information

The safety profile of Folisanin, whose active component is Folic Acid, is based on official government regulatory classifications that define adverse reactions by system-organ classes and frequency. The majority of reported effects are considered low-incidence and non-serious.


Officially Documented Adverse Reactions

The officially listed adverse reactions are categorized primarily within the Gastrointestinal Disorders and Immune System Disorders system-organ classes. Gastrointestinal effects such as nausea, flatulence (gas), and abdominal distension are generally reported as common in some regulatory documents. Hypersensitivity reactions, which are classified as rare, may manifest as skin reactions including rash, pruritus (itching), and erythema (reddening).

In rare instances, the regulatory labels document severe systemic reactions that constitute the highest tier of concern within the Immune System Disorders. These serious adverse reactions include anaphylactic reaction (anaphylaxis) and bronchospasm (severe breathing difficulty), which are potential, though isolated, manifestations of a generalized allergic response.


Critical Safety Restrictions

Folisanin is subject to a mandatory safety restriction concerning its use in the context of an undiagnosed anemia. The medication must not be used as the sole therapeutic agent to treat megaloblastic anemia caused by a Vitamin B12 deficiency (Pernicious Anemia). This restriction is critical because the Folic Acid can correct the hematological signs of the deficiency, thereby masking the ongoing, and potentially irreversible, neurological deterioration associated with the underlying Vitamin B12 deficiency.

An absolute contraindication to Folisanin use is a known hypersensitivity to the active substance, Folic Acid, or to any of the non-active ingredients in the specific preparation.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory profile for Folisanin (Folic Acid) indicates a low acute toxicity profile for oral formulations, meaning serious life-threatening outcomes are typically not documented following ingestion. Overdose is primarily reported after massive ingestion and the effects are generally self-limiting.


Documented Manifestations and Emergency Action

Official prescribing information documents specific, non-severe clinical manifestations associated with overdose. These typically affect the gastrointestinal system and include gastrointestinal disturbance, nausea, flatulence, and abdominal distention. Other documented systemic findings are minor, such as irritability and altered sleep patterns.

In the event of a suspected overdose, regulatory authorities mandate that immediate medical attention must be sought. Contact emergency services if ingestion is massive or if any symptoms are severe or concerning. Hospital monitoring may be required for observation.


Management Protocol

Management of Folisanin overdose is strictly defined as symptomatic and supportive treatment. Official documentation states that no specific antidote is known for Folic Acid overdose. Treatment procedures require the discontinuation of the medicinal product and clinical observation to manage documented manifestations.

Therapeutic Uses of Folisanin

Folisanin is used across clinical settings involving folate status and associated conditions, and is applied in addressing conditions and providing supportive therapeutic assistance. The use of the medication is relevant for addressing both hematological conditions and prenatal health, particularly in contexts involving heightened systemic burden related to blood and prenatal development.


Support for Deficiency Management and Prevention

The primary therapeutic applications include addressing folate-deficiency megaloblastic anemia and is relevant for easing the risk of Neural Tube Defects (NTDs). Folisanin is commonly used to help with symptoms related to systemic imbalance, such as chronic fatigue, persistent lack of energy, and mucosal irritation like a tender tongue. It assists with maintaining functional stability by supporting red blood cell formation in situations where systemic imbalance is present. The medication is also considered relevant for women of childbearing age for its important role in prevention, applied against the risk of serious birth defects like spina bifida and anencephaly.

“Folisanin contributes to improved day-to-day comfort during symptomatic periods by easing the overall symptom load associated with deficiency.”


Quick Fact: Support for Anemia Symptoms

Folisanin is specifically used when conditions present with symptoms that create noticeable physiological strain, typically helping patients cope more steadily with fatigue and general weakness linked to poor blood cell health.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility for Folisanin is defined by official regulatory bodies based on the underlying diagnosis and certain physiological states. Folisanin is widely permitted for use in adults with confirmed folate deficiency, as well as for prophylactic use in women of childbearing age and pregnant/lactating women to prevent Neural Tube Defects.

Population Group Regulatory Status
Populations for whom use is allowed: Adults with confirmed deficiency; pregnant/lactating women; patients with haemolytic anemia or undergoing renal dialysis.
Populations for whom use is contraindicated: Patients with known hypersensitivity to Folic Acid or excipients; patients with untreated cobalamin (Vitamin B12) deficiency; patients with certain malignant diseases (unless treating concurrent folate deficiency).

Eligibility-related Restrictions:

Folisanin is not recommended for use alone in patients with undiagnosed megaloblastic anemia, as this may mask the hematological signs of an underlying Vitamin B12 deficiency while allowing irreversible neurological damage to progress. Conditional use is required for the pediatric population, which depends on the specific formulation and condition being treated. Conditional use is also specified for patients receiving certain anti-epileptic drugs, where labeled warnings note potential for interference.

What should I know about interactions with other medicines?

The official interaction profile for Folisanin (Folic Acid) is defined by its potential for pharmacodynamic antagonism and alteration of drug exposure, strictly based on government regulatory documentation.

Interaction Restrictions and Antagonism

Folisanin is contraindicated as the sole treatment for megaloblastic anemia if a concurrent Vitamin B12 deficiency has not been excluded. The regulatory profile documents that co-administration with aromatic anticonvulsants, including Phenytoin and Phenobarbital, may result in a decrease in serum anticonvulsant levels, formally described as antagonism of therapeutic action. Folisanin may also decrease the therapeutic response to systemically administered Methotrexate and other folate antagonists (e.g., Pyrimethamine) due to documented pharmacodynamic interference. Additionally, co-administration with Fluorouracil may increase its toxicity.

Absorption and Systemic Status

Substances that reduce absorption, such as Cholestyramine and Antacids containing aluminium or magnesium, require specific timing separation rules. Antacids must be administered at least two hours after Folisanin to prevent reduced absorption. Chronic alcohol consumption is officially documented to increase Folic Acid elimination, which can result in deficiency. Furthermore, Sulfasalazine and Chloramphenicol may also interfere with Folisanin's status. Patients undergoing haemodialysis or those with chronic infection may have a documented increased daily maintenance requirement for Folic Acid.

Mechanism of Action

Folisanin (Folic Acid) exerts its action through its role as a metabolic precursor that provides necessary cofactors for cellular synthesis pathways. The mechanism focuses on enabling metabolic reactions by providing essential cofactors rather than directly blocking or activating a classical signaling receptor.


Key Mechanism: Fueling DNA Synthesis and Cell Maturation

Folisanin is inactive until it is converted by the enzyme Dihydrofolate Reductase (DHFR) into active folate cofactors. These cofactors are indispensable for the transfer of single-carbon units needed to synthesize the purine and thymidylate bases, which are the foundational building blocks of DNA. This action facilitates the rapid and correct division of cells, particularly in the bone marrow, contributing to the proper maturation of red blood cells (erythropoiesis).


One-Carbon Metabolism and Mechanistic Constraints

The active form of Folisanin engages the broader One-Carbon Metabolism pathway and the Methionine Cycle, acting as a cofactor alongside Vitamin B12 to convert the amino acid metabolite homocysteine into methionine. This physiological function involves the remethylation of homocysteine. However, this metabolic dependency creates a crucial mechanistic limitation: The mechanism's effect on hematopoietic tissue does not extend to the B12-dependent metabolic steps involved in neurological function.

Dosage and Administration Information

How to Use Folisanin

Folisanin must be administered exactly as prescribed, adhering to the provided instructions. The medicine is available in two primary dosage forms and corresponding routes of administration.


Dosage Forms and Approved Routes

Dosage Form Approved Route of Administration
Tablet Oral
Injection, Solution Intramuscular (IM), Intravenous (IV), Subcutaneous (SC)

Standard Dosing and Frequency

The standard adult and pediatric dose for treatment or maintenance is 1 mg daily by the oral route. For certain medical conditions, or in the presence of factors like chronic infection or alcoholism, the daily maintenance dose may be at least doubled, as noted in the prescribing information.

Administration Requirements

  1. Oral Administration: Tablets are typically taken once daily with or without food.
  2. Parenteral Administration: The injectable solution must be handled with care, as it is sensitive to heat and light. For specific regimens, the solution may be administered as an intravenous push over a defined duration (e.g., 3 to 5 minutes) and must only be delivered via the approved parenteral routes (IM, IV, SC).
  3. Dose Transition: Treatment protocols require a transition to a maintenance dose once the clinical parameters have normalized, ensuring adherence to the long-term protocol.

Recent Clinical Evidence

Folisanin, which is the synthetic form of the B-vitamin folate, has been the subject of continuous clinical research, particularly concerning its established roles and potential supplementary uses. The most significant and well-documented clinical evidence supports the use of Folisanin for the prevention and treatment of megaloblastic and macrocytic anemias caused by folate deficiency. It is considered an essential component in managing this condition to ensure proper red blood cell maturation and DNA synthesis.


Key Areas of Clinical Focus

Clinical trials and meta-analyses have reaffirmed the critical role of Folisanin supplementation in preventing Neural Tube Defects (NTDs), such as spina bifida, in newborns. The evidence strongly indicates that women of childbearing age, especially those planning to conceive, should maintain adequate folate intake to reduce the risk, as the vulnerable period for NTDs is very early in pregnancy.

Clinical Application Summary of Evidence Mechanism of Action
NTD Prevention Strong evidence from randomized controlled trials supports a significant risk reduction. Essential for proper cell division and development of the neural tube.
Homocysteine Reduction Proven efficacy in lowering elevated plasma homocysteine levels. Functions as a cofactor in the metabolic conversion of homocysteine to methionine.
Cardiovascular Risk Evidence suggests reduction of high homocysteine levels, a potential risk factor, but conclusive evidence of direct cardiovascular disease outcome benefit is mixed. Indirect benefit through homocysteine metabolism.

Recent investigations have continued to explore the relationship between Folisanin, the reduction of homocysteine levels, and overall cardiovascular health. While Folisanin is demonstrably effective at lowering high homocysteine concentrations—a known risk factor—clinical data regarding a definite, direct reduction in major cardiovascular events remains varied. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) primarily approve its use for the treatment of folate deficiency and the prevention of NTDs.

Frequently Asked Questions (FAQ)

Common questions about Folisanin (FAQ)


Q: What is the difference between Folisanin and other similar medicines in the same class?

A: Folisanin is the synthetic, man-made form of Vitamin B9, also known as Folic Acid. The body relies on an enzyme called Dihydrofolate Reductase (DHFR) to convert this synthetic form into the active folate cofactors. These active cofactors are necessary to help drive certain important metabolic processes, such as DNA synthesis.

Q: Why is Folisanin sometimes referred to by a different name?

A: Folisanin is the brand name, but the active ingredient is commonly referred to by several scientific and general names. These include Folic Acid, which is its generic name, and Vitamin B9, which is its classification as a water-soluble vitamin. Official documents may also refer to it by its chemical name, Pteroylglutamic acid.

Q: How common are the serious side effects listed for Folisanin?

A: According to official safety information, the most severe adverse reactions are considered rare occurrences. These severe allergic responses, which can include symptoms like fever, generalized weakness, or difficulty breathing (anaphylaxis), are isolated manifestations of a generalized allergic response. Most reported side effects are categorized as low-incidence and non-serious.

Q: What should I do if I think I'm having a mild side effect from Folisanin?

A: Official guidance typically recommends consulting a health care professional if a mild side effect is experienced. Mild stomach upset or gastrointestinal effects are sometimes eased by taking the medicine with or immediately after food.

Q: Does Folisanin interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Regulatory data on drug-drug interference suggests that interactions with common over-the-counter pain relievers like acetaminophen are typically considered minor. However, official safety guidelines recommend that a complete list of all medications and supplements being used should be reviewed with a health care professional before starting Folisanin.

Q: Are there any specific foods or beverages I should avoid while on Folisanin?

A: The official prescribing information notes that chronic alcohol consumption is documented to increase the rate at which Folic Acid is eliminated from the body, which can potentially lead to a deficiency. Outside of this warning regarding alcohol, there are no other specific food prohibitions or dietary restrictions typically mentioned on the regulatory label for Folisanin.

Q: How long does it usually take for Folisanin to start showing its intended effects?

A: When Folisanin is used to treat a deficiency, official sources describe a rapid initial effect on the bone marrow. The marrow may begin to normalize within the first 48 hours, with the production of new red blood cells (reticulocytosis) typically commencing within two to five days of starting the medicine.

Q: Does Folisanin need to be taken at a specific time of day or with food?

A: The tablet form of Folisanin is typically administered once daily and can be taken with or without food. While regulatory documents do not specify a mandatory time of day for dosing, consistency is often encouraged to maintain a steady routine.

Q: Is Folisanin the kind of treatment that requires long-term or indefinite use?

A: The duration of Folisanin treatment depends entirely on the cause of the deficiency being addressed. While initial treatment for deficiency may last a set period of months, if the underlying cause is a chronic or long-term physiological problem, official guidelines suggest that the medication may be required for an extended period, which could be indefinite.

Q: How often are follow-up appointments or monitoring tests generally recommended when taking Folisanin?

A: Official prescribing information stresses the importance of keeping patients under close supervision while taking Folisanin. This monitoring is particularly critical to ensure that any underlying Vitamin B12 deficiency is not masked, a situation that could allow neurological damage to progress. However, the regulatory label does not specify a fixed, routine frequency (like monthly or quarterly) for follow-up testing.

Q: Is Folisanin appropriate or studied for use in pediatric (child) patients?

A: Official regulatory guidance indicates that Folic Acid is an approved substance for use in pediatric patients (children), and the dosage is typically determined by a health care professional based on the specific condition being treated. For the recommended daily allowances, safety reports do not indicate problems in children when taking the appropriate amount.

Q: Are there special safety considerations for elderly or senior patients taking Folisanin?

A: Regulatory documentation does not report special problems or safety concerns in older adult (geriatric) patients when taking the normal daily recommended amounts of Folic Acid. However, general use requires a health care provider to consider all existing health conditions.

Q: Can Folisanin be used by people who have existing kidney or liver problems?

A: For individuals with severe kidney impairment, specifically those undergoing haemodialysis, the official documentation notes that an increased daily requirement for Folisanin may exist. The prescribing information suggests a careful approach (caution) in all patients with reduced kidney function, although the medicine is not strictly contraindicated in these populations.

Q: Where can I find the official, full prescribing information (package insert) for Folisanin?

A: The complete and official drug information, often called the full Prescribing Information or Summary of Product Characteristics (SmPC), is publicly available from government drug agencies. This information can be accessed on websites such as the U.S. Food and Drug Administration (FDA) or the relevant European Medicines Agency (EMA) product pages by searching for the active ingredient, Folic Acid.

Q: Why are there frequently new studies and research being published about Folisanin?

A: Research continues globally because Folic Acid is a fundamental micronutrient with roles in many body processes. Studies are often published to explore potential connections between Folisanin supplementation and long-term health, including areas like cardiovascular health, cognitive function, and cancer prevention, which extend beyond its established and approved uses.

Q: Does Folisanin cause changes in body weight or appetite?

A: The official safety profile for Folisanin does not typically list body weight changes as a common adverse reaction. However, anorexia (loss of appetite) has been reported in patients who are receiving high daily doses of Folic Acid.

Q: Is it true that Folisanin can affect your sleep cycle?

A: Yes, altered sleep patterns are listed among the possible side effects in regulatory documents. Specifically, issues such as insomnia (difficulty sleeping) have been reported in some patients who were taking higher-than-usual daily doses of Folic Acid.

Q: What is the recommended procedure for reporting a side effect related to Folisanin?

A: Regulatory authorities provide official systems for patients to report any suspected side effects. Examples include the FDA MedWatch program in the U.S. and the MHRA Yellow Card Scheme in the U.K. These official mechanisms are available for use in reporting adverse events in the relevant country.

Q: Does Folisanin have any known long-term effects that people should monitor?

A: Official regulatory warnings highlight a critical concern for long-term use: taking Folic Acid can potentially mask the blood-related signs of a Vitamin B12 deficiency. This masking effect allows irreversible neurological damage, associated with the B12 deficiency, to progress undetected, which is why monitoring for Vitamin B12 status may be necessary during therapy.

Q: Can Folisanin make you feel dizzy, drowsy, or affect your ability to concentrate?

A: Official safety documentation lists effects on the central nervous system that have been reported, primarily when the medication is used at high doses. These effects include difficulty concentrating, confusion, and temporary impaired judgment.

Q: Is it safe to take Folisanin with daily vitamins, like Vitamin C or D?

A: Most common vitamins, such as Vitamin C or Vitamin D, are not specifically reported to interact with Folisanin. However, regulatory bodies advise that Folic Acid doses exceeding the standard Recommended Dietary Allowance (RDA) should generally not be included in over-the-counter multivitamin preparations unless an underlying B12 deficiency has been medically excluded.

Q: Does Folisanin have an interaction warning with hormonal birth control pills?

A: Official sources, including government health bodies, state that Folic Acid is not known to affect the efficacy of hormonal contraception. This means that Folisanin does not stop the combined hormonal birth control pill or other forms of contraception from working as intended.

Q: What does the product labeling recommend if an occasional dose of Folisanin is forgotten?

A: The official product labeling provides specific guidance for handling a missed dose. The principle of this guidance is to skip the missed dose and resume the regular schedule rather than taking extra medication to compensate. The label strictly specifies that doses should not be doubled.

How should Folisanin be stored and disposed of?

Folisanin (Folic Acid) must be stored under specific regulatory conditions to maintain its stability and effectiveness.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically 20^circmathrmC to 25^circmathrmC. It is mandatory to keep the product protected from light, heat, and moisture. To prevent accidental ingestion, Folisanin must be stored out of the reach and sight of children, and must be kept in its original, well-closed container which should feature a child-resistant closure. The medicine must not be used after the expiration date printed on the package.

Disposal Instructions

Expired or unused Folisanin must not be thrown into household trash or flushed down the toilet. Disposal must be carried out in accordance with local regulations for pharmaceutical waste to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Folisanin found in:

A-Z Index: